CC
STOK icon

Checkpoint Capital’s Stoke Therapeutics STOK Stock Holding History

Checkpoint Capital’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-212,049
Closed -$4.98M – 10
2025
Q3 		$4.98M Buy
+212,049
New +$3.63M 1.67% 8
2025
Q2 		– Sell
-730,717
Closed -$4.86M – 13
2025
Q1 		$4.86M Buy
730,717
+425,330
+139% +$3.97M 2.67% 7
2024
Q4 		$3.37M Buy
305,387
+147,873
+94% +$1.82M 1.71% 12
2024
Q3 		$1.94M Buy
+157,514
New +$2.23M 0.96% 13

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Checkpoint Capital's STOK Position: Q4 2025 in Review

Checkpoint Capital sold out of Stoke Therapeutics (STOK) in Q4 2025, closing a stake of 212,049 shares — an estimated $4.98M sold.

Checkpoint Capital first reported a position in STOK in Q3 2024 and held it in 4 quarters. The position peaked at $4.98M in Q3 2025. 183 funds tracked by Wall St. Rank hold STOK as of Q4 2025.

  • Checkpoint Capital reported no remaining Stoke Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Checkpoint Capital sold 212,049 Stoke Therapeutics shares in Q4 2025, an estimated $4.98M.
  • Checkpoint Capital first reported a position in Stoke Therapeutics in Q3 2024 and held it in 4 quarters.
  • Checkpoint Capital's Stoke Therapeutics position peaked at $4.98M in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2025.

Based on Checkpoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.